Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Purpose
Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine.
Patients and Methods
To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 weeks, or twice daily for 3 days for 2 weeks (days 1 through 3 and days 8 through 10) every 3 to 4 weeks, in refractory-relapse acute leukemia and myelodysplastic syndrome (MDS). A total of 47 patients were treated in the phase I study that used a classical 3 + 3 design. Sapacitabine was escalated from 75 to 375 mg twice daily for 7 days (n = 35) and from 375 to 475 mg twice daily for 3 days on days 1 through 3 and days 8 through 10.
Results
The DLTs with both schedules were gastrointestinal. The MTDs were 375 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. The recommended phase II single-agent dose schedules were 325 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Responses were observed in 13 patients (28%); four were complete responses, and nine were marrow complete responses.
Conclusion
Sapacitabine is a new, safely administered, oral deoxycytidine analog that has encouraging activity in leukemia and MDS. Phase II studies are ongoing.
Топ-30
Журналы
|
1
2
3
4
|
|
|
Molecular Cancer Therapeutics
4 публикации, 6.78%
|
|
|
Current Hematologic Malignancy Reports
3 публикации, 5.08%
|
|
|
Clinical Lymphoma, Myeloma and Leukemia
3 публикации, 5.08%
|
|
|
Expert Opinion on Pharmacotherapy
3 публикации, 5.08%
|
|
|
Seminars in Oncology
2 публикации, 3.39%
|
|
|
Blood Reviews
2 публикации, 3.39%
|
|
|
Expert Opinion on Investigational Drugs
2 публикации, 3.39%
|
|
|
Acta Haematologica Polonica
2 публикации, 3.39%
|
|
|
Blood
2 публикации, 3.39%
|
|
|
Current Opinion in Hematology
1 публикация, 1.69%
|
|
|
Journal of Experimental and Clinical Cancer Research
1 публикация, 1.69%
|
|
|
Chromatographia
1 публикация, 1.69%
|
|
|
Annals of Hematology
1 публикация, 1.69%
|
|
|
Bone Marrow Transplantation
1 публикация, 1.69%
|
|
|
Targeted Oncology
1 публикация, 1.69%
|
|
|
Cancer Chemotherapy and Pharmacology
1 публикация, 1.69%
|
|
|
Current Treatment Options in Oncology
1 публикация, 1.69%
|
|
|
Nature Reviews Drug Discovery
1 публикация, 1.69%
|
|
|
Nature Reviews Clinical Oncology
1 публикация, 1.69%
|
|
|
British Journal of Cancer
1 публикация, 1.69%
|
|
|
Leukemia
1 публикация, 1.69%
|
|
|
Critical Reviews in Oncology/Hematology
1 публикация, 1.69%
|
|
|
Antiviral Research
1 публикация, 1.69%
|
|
|
Clinics in Geriatric Medicine
1 публикация, 1.69%
|
|
|
Seminars in Hematology
1 публикация, 1.69%
|
|
|
The Lancet Oncology
1 публикация, 1.69%
|
|
|
Bioorganic and Medicinal Chemistry Letters
1 публикация, 1.69%
|
|
|
Annals of Oncology
1 публикация, 1.69%
|
|
|
Leukemia Research
1 публикация, 1.69%
|
|
|
1
2
3
4
|
Издатели
|
2
4
6
8
10
12
14
16
|
|
|
Elsevier
16 публикаций, 27.12%
|
|
|
Springer Nature
14 публикаций, 23.73%
|
|
|
Taylor & Francis
8 публикаций, 13.56%
|
|
|
American Association for Cancer Research (AACR)
5 публикаций, 8.47%
|
|
|
Wiley
3 публикации, 5.08%
|
|
|
American Society of Hematology
3 публикации, 5.08%
|
|
|
Walter de Gruyter
2 публикации, 3.39%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 публикация, 1.69%
|
|
|
Oxford University Press
1 публикация, 1.69%
|
|
|
Hindawi Limited
1 публикация, 1.69%
|
|
|
American Society of Clinical Oncology (ASCO)
1 публикация, 1.69%
|
|
|
2
4
6
8
10
12
14
16
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.